Search research articles
Contact Us
Filters
Showing results (161-170 of 308) with videos related to
Page
of 31
Sort By:
Blood Advances
|
August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Maria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
British Journal of Haematology
|
November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)
Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
Blood Advances
|
September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM
Marietta S Truger, Johannes Duell, Xiang Zhou, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2024
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, et al.
Blood
|
January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Max S Topp, Matthew Matasar, John N Allan, et al.
The Lancet. Haematology
|
April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
American Journal of Cancer Research
|
July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
Tom van Meerten, John Kuruvilla, Kevin W Song, et al.
Haematologica
|
February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.
European Journal of Immunology
|
July 28, 2023
Enolase 1 of Candida albicans binds human CD4<sup>+</sup> T cells and modulates naïve and memory responses
Muhammad Daud, Prasad Dasari, Marion Adelfinger, et al.
Blood
|
August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma
Pier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
Page
of 31
Search research articles
Search
Showing results (161-170 of 308) with videos related to
Sort By:
Page
of 31
Blood Advances
|
August 21, 2023
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Maria-Luisa Schubert, Wolfgang A Bethge, Francis A Ayuk, et al.
British Journal of Haematology
|
November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)
Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
Blood Advances
|
September 2, 2021
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM
Marietta S Truger, Johannes Duell, Xiang Zhou, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2024
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, et al.
Blood
|
January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Max S Topp, Matthew Matasar, John N Allan, et al.
The Lancet. Haematology
|
April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
American Journal of Cancer Research
|
July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
Tom van Meerten, John Kuruvilla, Kevin W Song, et al.
Haematologica
|
February 13, 2023
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia
Nicola Gökbuget, Kristina Ihrig, Michael Stadler, et al.
European Journal of Immunology
|
July 28, 2023
Enolase 1 of Candida albicans binds human CD4<sup>+</sup> T cells and modulates naïve and memory responses
Muhammad Daud, Prasad Dasari, Marion Adelfinger, et al.
Blood
|
August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma
Pier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
Page
of 31